| Status: Under consideration by AWMSG Scrutiny Panel | |
First line (off-label) treatment for paediatric patients aged 1 month to 17 years diagnosed with CD19 positive, B-cell precursor acute lymphoblastic leukaemia (ALL) alongside standard chemotherapy. |
|
Medicine details |
|
| Medicine name | blinatumomab (Blincyto®) |
| Formulation | infusion |
| Reference number | 6520 |
| Indication | As above |
| Company | Amgen Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | One Wales |
| Status | Under consideration by AWMSG Scrutiny Panel |
| Scrutiny Panel meeting date | 10/04/2025 |